Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 17/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080592 | 0.85 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3816816 | 0.82 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4083459 | 0.80 | SLC6A2 (0.79) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3820677 | 0.79 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4719280 | 0.78 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4077212 | 0.73 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4087061 | 0.73 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL4079983 | 0.72 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4077415 | 0.69 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4085254 | 0.69 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091933-A1 | DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20080153873-A1 | DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-26 | — | — | US | disclosed |
| WO-2008073943-A1 | DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153873-A1 | DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE | DBH, SLC6A3, SLC6A4 | SLC6A2 5/4885SLC6A4 3/4885SLC6A3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.